Exhibit
99.1

Daré
Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
DARE
to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and
Washington, D.C.
Commercial
launch of Flora Sync LF5™ showing encouraging early indicators, including orders from 27 states, provider office reorder and positive
consumer feedback
Company
surpassed $43 million in cumulative non-dilutive grant funding supporting advancement of DARE-LARC1; exploring potential strategic collaboration
opportunities in areas including obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1
medicines, for the underlying DARE-IDDS platform
Company
to host conference call and webcast today, November 16, 2026, at 4:30 p.m. Eastern Time – Access the webcast here
SAN
DIEGO, November 16, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company
solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial
results for the quarter ended September 30, 2026 and provided a corporate update highlighting commercial execution and continued progress
with its development pipeline.
“This
is an exciting day for clinicians and women waiting for DARE to PLAY Sildenafil Cream, as the first shipment is on route from the outsourcing
facility to Medvantx, the central pharmacy that handles order processing and dispensing. DARE to PLAY provider engagement built demand
ahead of dispensing, with prescriptions written across 48 states and Washington, D.C. Our outsourcing facility partner has been working
to manufacture supply at a scale to meet anticipated demand, and, with product now on route to Medvantx, we expect prescription dispensing
to commence later this month,” said Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience.

“For
Flora Sync LF5 we built our initial commercial approach around the relationships women have with their healthcare providers, given the
clinical data that distinguish Flora Sync LF5 in the category, and the early response to Flora Sync LF5 is encouraging. Recommendations
and sampling are helping women discover the product, while our provider office reorder gives us an early indication of repeat demand,”
continued Ms. Johnson. “Our priority now is to build on that response and turn initial purchases into sustained growth. We look
forward to launching Flora Sync LF5 on Amazon in early 2027, and are pleased to be expanding the DARE to RESTORE™ brand family
to include Flora Renew™ and Flora Reset™, a vulvar mask and cleanser, also anticipated in early 2027.”
BUILDING
TOWARD A MULTI-PRODUCT COMMERCIAL PORTFOLIO
Daré
Bioscience is building a commercial platform designed to make it easier for women to discover, access and purchase products developed
specifically for their health needs. The Company’s approach is to bring together evidence-based products, healthcare provider engagement
and sampling, targeted digital marketing, telehealth services and the DARE Health Hub to support adoption and repeat purchases across
a growing commercial portfolio.
Key
Commercial Highlights:
| |
● |
Flora Sync LF5™:
Launched in June 2026, with first sales in July, Flora Sync LF5 is Daré Bioscience’s first directly commercialized
product and initial consumer health offering. Available through the DARE Health Hub and directly to healthcare providers for in-office
dispensing, the product has generated orders from 27 states and its first provider office reorder. Early consumer feedback includes
a 4.9-star review rating after the initial approximately 25 reviews, with customers reporting purchases following a provider recommendation
or sample. The Company continues clinician education, sampling and provider outreach to build recommendations, repeat office purchases
and consumer demand. |
| |
|
|
| |
● |
DARE to PLAY™ Sildenafil
Cream*: Daré Bioscience is preparing for prescription dispensing of its proprietary topical sildenafil cream through the
Section 503B compounding pathway, with dispensing expected this month in 28 states. The Company has worked with its 503B-registered
outsourcing facility partner to prepare to supply at a scale to support anticipated demand, as well as to continue efforts to obtain
licenses to dispense DARE to PLAY Sildenafil Cream in the remaining states. Provider engagement has generated prescriptions from 182
office-based prescribers, excluding telehealth. Across office-based providers and telehealth, prescriptions have been written in 48
states and Washington, D.C. |

| |
● |
DARE to RECLAIM™*:
Daré Bioscience is preparing for commercial availability of its monthly estradiol and progesterone intravaginal ring through
the Section 503B compounding pathway, with prescription dispensing targeted to begin in 2027. In parallel, the Company plans to continue
conventional drug product development necessary to pursue a regulatory strategy using the FDA’s 505(b)(2) pathway. |
| |
|
|
| |
● |
DARE Health Hub: The
Company’s digital commercial platform continues to support product discovery, education, access and fulfillment, providing infrastructure
intended to support current and future product offerings. |
ADVANCING
A DIFFERENTIATED WOMEN’S HEALTH PIPELINE
Daré
Bioscience continues to progress a diversified pipeline to address significant unmet needs across women’s health, supported in
part by non-dilutive grant funding.
“Non-dilutive
funding is central to how we develop our pipeline. We have secured more than $75 million in grant awards to provide funding support for
our programs that does not dilute our shareholders, and we continue to pursue additional funding opportunities,” added Ms. Johnson.
“That investment is also creating opportunities beyond the programs it initially supported. DARE-IDDS, our programmable drug delivery
technology underlying our DARE-LARC1 contraceptive program, is designed to control how much drug is released and when. This tunability
has potential applications in obesity, diabetes, hormone therapies and neurological diseases. We are exploring potential strategic collaborations
for the platform into these areas, with the goal of reducing the burden of frequent injections or daily dosing.”
| |
● |
Ovaprene® – Investigational
Hormone-Free Monthly Intravaginal Contraceptive: Daré Bioscience previously reported positive interim results from its ongoing
pivotal Phase 3 study of Ovaprene (ClinicalTrials.gov ID: NCT06127199), and the independent Data Safety Monitoring Board’s recommendation
that the study continue without modification. The Company continues to anticipate reporting topline data from the study in 2027. The
program remains a key component of Daré Bioscience’s clinical pipeline and is supported by grant funding from the Gates
Foundation. |
| |
|
|
| |
● |
DARE-HPV – Investigational
Therapeutic for Persistent High-Risk HPV Infection: Daré Bioscience is advancing its Phase 2 clinical study of DARE-HPV,
an investigational fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, to evaluate the safety and antiviral
activity of DARE-HPV in women with persistent high-risk human papillomavirus (HPV) infection (ClinicalTrials.gov ID: NCT07601074).
The study is expected to enroll approximately 100 women, with topline results anticipated in 2027. The program is supported by funding
from the Advanced Research Projects Agency for Health (ARPA-H) and the National Institute of Allergy and Infectious Diseases (NIAID)
of the National Institutes of Health. There are currently no FDA-approved pharmacologic treatments for HPV infection. |

| |
● |
DARE-PTB2 – Investigational
Program for the Prevention of Preterm Birth: Daré Bioscience continues to advance DARE-PTB2, an early-stage program focused
on a novel therapeutic approach intended to address biological mechanisms associated with preterm birth, supported by an approximately
$0.9 million grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National
Institutes of Health announced in August 2026. |
| |
|
|
| |
● |
DARE-LARC1 – Investigational
Long-Acting Reversible Contraceptive: Daré Bioscience continues to advance preclinical development of DARE-LARC1, a grant-supported
contraceptive program built on the Company’s programmable drug delivery technology. The underlying DARE-IDDS platform is designed
to control the amount of drug released and the timing of release, offering potential flexibility in how medicines are delivered. |
| |
|
|
| |
● |
DARE-IDDS – Investigational
Programmable Drug Delivery Platform: DARE-IDDS is the underlying technology behind DARE-LARC1 and is designed to control how much
drug is released and when. Daré Bioscience believes this tunability may have broader applications across chronic conditions
and is exploring potential strategic collaboration opportunities in areas including obesity, diabetes, hormone therapies and neurologic
disease, including potential applications with GLP-1 medicines. |
NON-DILUTIVE
GRANT FUNDING
Daré
Bioscience has secured more than $75 million in non-dilutive grant awards as part of its strategy to fund development across its women’s
health pipeline while limiting shareholder dilution. The Company continues to pursue additional grant funding to support its programs
and expand development opportunities.
Recent
Grant Awards:
| |
● |
Ovaprene and Contraceptive
Product Candidate: In November 2026, Daré Bioscience received a payment of approximately $0.9 million under its November
2024 grant agreement with the Gates Foundation supporting the ongoing Phase 3 clinical trial of Ovaprene and the identification and
development of a novel non-hormonal intravaginal contraceptive candidate. This payment represents the next-to-last anticipated tranche
under the up to approximately $10.7 million grant award. Daré Bioscience received approximately $5.4 million in funding under
the agreement in 2024 and approximately $3.6 million in 2025. |
| |
|
|
| |
● |
DARE-LARC1: In October
2026, Daré Bioscience received a $1.5 million payment under its June 2021 grant agreement supporting development of DARE-LARC1.
Including this payment, the Company has received approximately $43.3 million of the up to $49.0 million in potential funding under
the agreement. |

FINANCIAL
RESULTS FOR THIRD QUARTER 2026 AND HIGHLIGHTS
Cash
Position
As
of September 30, 2026, Daré Bioscience had approximately $11.5 million in cash and cash equivalents and working capital of approximately
$3.2 million.
Revenue
Total
revenue for the three months ended September 30, 2026 was approximately $48,000, compared to approximately $2,300 for the same period
of the prior year. The increase was primarily attributable to research and development services revenue under agreements entered into
with the Gates Foundation in September and October 2025. Third quarter 2026 revenue includes revenue from sales of Flora Sync LF5, which
began in July 2026.
Cost
of Revenues
Cost
of revenues for the three months ended September 30, 2026 was approximately $0.2 million, with no comparable activity in the same period
of the prior year. Cost of revenues primarily related to expenses associated with medical education and awareness related to the commercialization
of DARE to PLAY.
Operating
Expenses
Selling,
general and administrative expenses were approximately $2.6 million for the three months ended September 30, 2026, compared to approximately
$2.5 million for the same period of the prior year. The increase of approximately $0.1 million was primarily attributable to increased
commercial-readiness expenses associated with execution of the Company’s expanded business strategy, increased stock-based compensation
and personnel costs, and a non-cash write-down of previously deferred offering costs, partially offset by decreases in general corporate
overhead expenses and professional services.

Research
and development (R&D) expenses were approximately $0.3 million for the three months ended September 30, 2026, compared to approximately
$1.2 million for the same period of the prior year. The decrease was primarily attributable to decreased costs for several development
programs, including Sildenafil Cream and DARE to PLAY Sildenafil Cream, DARE-LARC1, and Ovaprene. These decreases were partially offset
by increased expenses related to other advanced clinical-stage programs, primarily DARE-HPV, and decreased contra-R&D expenses associated
with direct program costs for grant-supported programs.
Daré
Bioscience recognizes amounts received under grant and governmental funding awards as “contra-R&D expenses,” meaning
grant funding reduces R&D expenses in the statements of operations as the related costs are incurred over the grant period. The Company
believes this is important to understand when evaluating the scale of the Company’s R&D investment and capital efficiency.
Total contra-R&D expenses for the three months ended September 30, 2026 and 2025 were approximately $4.7 million and $5.0 million,
respectively.
Net
Loss
Net
loss for the three months ended September 30, 2026 was approximately $3.2 million, compared to approximately $3.6 million for the same
period of the prior year.
Revenue
Outlook
Daré
Bioscience began recording revenue from sales of Flora Sync LF5 in July 2026 and expects to begin recording revenue from sales of DARE
to PLAY Sildenafil Cream in the fourth quarter of 2026. The Company does not expect the amount of such product revenue to be material
during 2026. Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring is targeted to begin in 2027. The Company is building
toward a multi-product revenue profile that diversifies and grows across 2026 and 2027.
Daré
Bioscience encourages investors to review the detailed discussion of its financial statements, financial condition, liquidity, capital
resources and risk factors in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed today with the U.S. Securities
and Exchange Commission (SEC).

Conference
Call
Daré
Bioscience will host a conference call and live webcast today, November 16, 2026, at 4:30 p.m. Eastern Time to review its financial results
for the quarter ended September 30, 2026, and to provide a company update.
To
access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5942376.
The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the
company’s website at ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register
and to download and install any necessary software. The webcast will be archived in the same section of the company’s website and
available for replay for 90 days.
ABOUT
DARÉ BIOSCIENCE, INC.
Daré
Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between
promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed
by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease,
Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told
to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the
regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting.
However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.
FORWARD-LOOKING
STATEMENTS
Daré
Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking
statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “prepare,” “progress,” “seek,”
“should,” “would,” “build,” “grow,” “pursue,” “target,” or the
negative version of these words and similar expressions.
In
this press release, forward-looking statements include, but are not limited to, statements relating to: Daré Bioscience’s
commercial strategy and plans, including anticipated products and their timing to market; the significance of the number, source and
geographic scope of prescriptions for DARE to PLAY received during the pre-fulfillment period; the significance of the number of states
from which Flora Sync LF5 has been ordered, the first provider office reorder and early consumer reviews of the product; the capabilities
of the Company’s commercial infrastructure and potential expansion of the platforms through which products may be sold; the ability
of the outsourcing facility to provide sufficient quantities of DARE to PLAY to meet anticipated demand and to obtain required state
licensing to dispense DARE to PLAY in additional states; the timing and materiality of future product revenue; the potential demand and
market opportunity for the Company’s products and their ability to gain market acceptance; potential commercial portfolio expansion;
development and regulatory pathway plans and expectations regarding the Company’s investigational products, including regulatory
strategy, clinical development strategies, clinical study timelines, and timing of topline results announcements; the potential for product
candidates in clinical and preclinical development to demonstrate safety and effectiveness for the respective indications for which they
are being developed; the potential for DARE-HPV to advance in clinical development and in the future become the first pharmacologic treatment
approved for the treatment of HPV infection; the potential application of DARE-IDDS for therapeutic products in a broad range of conditions
and diseases; expectations regarding non-dilutive funding, including the anticipated impact of funding received to date and the potential
to obtain additional non-dilutive funding awards; expectations regarding existing and potential future strategic collaborations; and
the potential for products that the Company brings to market to address significant unmet needs in women’s health.

Forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results,
performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking
statements in this press release, including, without limitation, risks and uncertainties related to: the Company’s ability to obtain
additional capital when and as needed to execute its business strategy and continue as a going concern; potential suspension and delisting
of the Company’s common stock from the Nasdaq Capital Market; the Company’s dependence on grants and other financial awards
from governmental entities and a private foundation and the risk that anticipated funding may be reduced, delayed, or terminated, or
may be insufficient to advance a product candidate into or through a particular development milestone as anticipated; the Company’s
reliance on Section 503B-registered outsourcing facilities and other third parties to bring DARE to PLAY Sildenafil Cream and other solutions
to market as compounded drugs or as consumer health products and facilitate access to such products and the risk that those third parties
do not perform as expected; difficulties in establishing and sustaining relationships with third-party collaborators; the risk that the
U.S. Food and Drug Administration (FDA) could stop permitting Section 503B-registered outsourcing facilities to compound the drug substances
in the proprietary formulations the Company intends to bring or brings to market or changes the conditions under which those drug substances
may be used in compounding or the compounded products may be distributed; the ability of outsourcing facilities with which the Company
collaborates to maintain their registration with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act; the timing of
establishing, and ability to maintain, state-required licensure or registration to enable fulfillment of prescriptions for DARE to PLAY
Sildenafil Cream and other solutions brought to market via the Section 503B pathway; the Company’s inexperience, as a company,
in and limited infrastructure for commercializing products; the degree of market demand and acceptance for the products the Company brings
to market; competitive product launches; greater than expected costs to bring compounded drug products to market and marketing costs;
shifts in consumer spending or behavior; failure or delay in commencing, conducting or completing clinical trials on anticipated timelines,
or at all, and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in technological proof-of-concept
studies, other nonclinical studies and/or early clinical studies of a product candidate or technology may not be predictive of success
in subsequent clinical and/or nonclinical studies of that candidate or technology; the risk that interim results from a particular clinical
study do not predict the final results for that study; decisions not to make clinical study design modifications recommended by the FDA;
the risk that even if a pivotal clinical study achieves its primary efficacy endpoint, the FDA may determine the data package is not
sufficient to support a favorable benefit-risk determination in a future marketing application; the Company’s dependence on third
parties to conduct clinical and nonclinical studies and manufacture and supply clinical trial material and commercial product; the potential
that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign
regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors
may not accept or agree with Daré Bioscience’s interpretation of or conclusions regarding data from clinical studies of
its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré
Bioscience anticipates; the risk that the FDA’s 505(b)(2) pathway** may not be available for a product candidate as Daré
anticipates; failure of the Company’s product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing
and reimbursement from third-party payors; the loss of, or inability to attract, key personnel; the Company’s ability to retain
its licensed rights to develop and commercialize a product or product candidate; the Company’s ability to satisfy the monetary
obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related
intellectual property related to its product and product candidates; the Company’s ability to adequately protect or enforce its,
or its licensor’s, intellectual property rights; disputes or other developments concerning the Company’s intellectual property
rights; the lack of patent protection for the active ingredients in certain of the Company’s product candidates which could expose
its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations
or actions relating to the Company’s products or product candidates or the business activities of the Company’s, its commercial
collaborators or other third parties on which the Company relies; changes in healthcare, pharmaceutical, consumer protection or privacy
laws and regulatory policies; increased scrutiny from regulators; global trends toward health care cost containment; the effects of macroeconomic
conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on the Company’s
ability to raise additional capital or on the Company’s operations, financial results and condition, and ability to achieve current
plans and objectives; and cybersecurity incidents or similar events that compromise the Company’s technology systems and/or significantly
disrupt the Company’s business or those of third parties on which it relies.

Daré
Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize
or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.
For a detailed description of the Company’s risks and uncertainties, you are encouraged to review its documents filed with the
U.S. Securities and Exchange Commission (SEC), including the Company’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You
are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré
Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date
on which they were made, except as required by law.
*The
terms DARE to PLAY and DARE to RECLAIM describe 503B compounded drug products. Compounded drug products are not approved by the FDA.
The FDA does not evaluate compounded drug products for safety, effectiveness, or quality. References to Section 503B, 503B, 503B compounding,
503B compounded product, and similar terms refer to Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) and the production
and supply of compounded drugs by Section 503B-registered outsourcing facilities without patient-specific prescriptions in accordance
with Section 503B. Section 503B-registered outsourcing facilities are subject to FDA inspection and required to compound drug products
under current Good Manufacturing Practice (cGMP) regulations to ensure quality, strength and consistency.
**The
term FDA 505(b)(2) regulatory pathway refers to Section 505(b)(2) of the FDCA, which enables an applicant to rely, in part, on the FDA’s
prior findings of safety and efficacy data for an existing product, or published literature, in support of the applicant’s new
drug application (NDA), providing an alternate path to FDA approval for new or improved formulations or new uses of previously approved
drugs.
Contact:
Daré
Bioscience Investor Relations
innovations@darebioscience.com
Source:
Daré Bioscience, Inc.

Daré
Bioscience, Inc. and Subsidiaries
Consolidated
Statements of Operations and Comprehensive Loss
(Unaudited)
| | |
Three
Months Ended September 30, | |
| | |
2026 | | |
2025 | |
| Revenue | |
| | | |
| | |
| Research
and development services and other revenue | |
$ | 47,628 | | |
$ | 2,262 | |
| Total
revenue | |
| 47,628 | | |
| 2,262 | |
| Cost
of revenues | |
| 180,479 | | |
| - | |
| Operating
expenses | |
| | | |
| | |
| Selling,
general and administrative | |
$ | 2,640,388 | | |
$ | 2,499,242 | |
| Research
and development | |
| 318,906 | | |
| 1,175,168 | |
| Total
operating expenses | |
| 2,959,294 | | |
| 3,674,410 | |
| Loss from
operations | |
| (3,092,145 | ) | |
| (3,672,148 | ) |
| Other
(expense) income, net | |
| (65,791 | ) | |
| 109,382 | |
| Net
loss | |
$ | (3,157,936 | ) | |
$ | (3,562,766 | ) |
| Foreign
currency translation adjustments | |
$ | 6,586 | | |
$ | 6,860 | |
| Comprehensive
loss | |
$ | (3,151,350 | ) | |
$ | (3,555,906 | ) |
| Loss
per common share - basic and diluted | |
$ | (0.18 | ) | |
$ | (0.28 | ) |
| Weighted average number of
shares outstanding: | |
| | | |
| | |
| Basic
and diluted | |
| 17,421,580 | | |
| 12,755,112 | |
Daré
Bioscience, Inc. and Subsidiaries
Condensed
Consolidated Balance Sheets Data
| | |
September
30, 2026 | | |
December
31, 2025 | |
| | |
(unaudited) | | |
| |
| Cash
and cash equivalents | |
$ | 11,531,684 | | |
$ | 24,711,356 | |
| Working
capital | |
$ | 3,210,505 | | |
$ | 3,378,192 | |
| Total assets | |
$ | 22,098,552 | | |
$ | 32,474,563 | |
| Total stockholders’
equity | |
$ | 2,341,375 | | |
$ | 2,842,634 | |